Jasper Therapeutics (JSPR) Tops Q2 EPS by 12c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/3/2026
- Wall St futures tepid as Middle East tensions keep investors wary
- Broadcom raises AI chip forecast as Big Tech keeps writing bigger checks
- Nvidia to acquire AI platform Hugging Face in landmark $12.9B deal
- Tesla to unveil Cybercab Texas today, details are few
- Snowflake soars 20% on earnings beat and raised guidance
Jasper Therapeutics (JSPR) PT Lowered to $68 at RBC Capital
August 14, 2024 6:25 AM EDTRBC Capital analyst Gregory Renza lowered the price target on Jasper Therapeutics (NASDAQ: JSPR) to $68.00 (from $70.00) while maintaining a Outperform rating.
The analyst comments "JSPR provided the updated timeline for briq's initial BEACON readout (CSU), now confirmed for 4Q24... More
